Prexton Therapeutics clinical trials
Acquired by H. Lundbeck A/S
The registry lists 3 studies whose lead sponsor is Prexton Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 17, 2020.
Status
- Completed
- 2
- Withdrawn
- 1
Registry sponsor names on this page
- Prexton Therapeutics3 studies
Something wrong with this grouping? Tell us on the H. Lundbeck A/S page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All H. Lundbeck A/S studies →
- Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsCompletedNCT03162874Phase 2
Sponsor listed in the registry: Prexton Therapeutics · Prexton Therapeutics — acquired company within the H. Lundbeck A/S group
- Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)WithdrawnNCT03331848Phase 2
Sponsor listed in the registry: Prexton Therapeutics · Prexton Therapeutics — acquired company within the H. Lundbeck A/S group
- A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsCompletedNCT02639221Phase 1
Sponsor listed in the registry: Prexton Therapeutics · Prexton Therapeutics — acquired company within the H. Lundbeck A/S group